Tuesday, January 24, 2017

BRIEF-Onxeo completes enrollment in phase III study of Livatag for the treatment of hepatocellular carcinoma

* Onxeo completes enrollment in phase III study of Livatag for the treatment of

hepatocellular carcinoma

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)